Systemic inflammation in acute myocardial infarction patients was associated with an increased risk of 3-point MACE compared to those without inflammation (HR 1.39; 95% CI 1.08-1.78).
Cohort (n=3,149)
Yes
Does systemic inflammation increase the risk of major adverse cardiovascular events and heart failure in patients with acute myocardial infarction?
In patients with acute myocardial infarction, the presence of systemic inflammation (hsCRP 2-10 mg/L) is associated with a significantly higher risk of subsequent MACE and incident heart failure hospitalizations.
Effect estimate: HR 1.39 (95% CI 1.08-1.78)
Absolute Event Rate: 45.4% vs 27.3%
Assess the association of systemic inflammation (SI) with major adverse cardiovascular events (MACE) and heart failure (HF) in patients with acute myocardial infarction (AMI). This retrospective cohort study included adults hospitalized for type 1 AMI from July 2016 through December 2023 in the Komodo Healthcare Map database. High-sensitivity C-reactive protein (hsCRP) test results 1 year before or after admission determined SI status (with SI, ≥1 test 2–10 mg/L; without SI, all tests 10 mg/L were excluded. Incidence of revised 3-point MACE (nonfatal MI, nonfatal stroke, or all-cause mortality), revised 4-point MACE (nonfatal MI, nonfatal stroke, urgent revascularization, or all-cause mortality), and HF were estimated per 1,000 person-years (PY). Cox regression models assessed the adjusted association between SI and the outcomes. Among 3,149 eligible patients (mean age, 61 years), 46.4% had SI. Compared with patients without SI, patients with SI were more likely to be female and have more comorbidities. Patients with SI had a higher incidence of revised 3-point (45.4 vs. 27.3/1,000PY) and 4-point MACE (52.1 vs. 35.1/1,000PY). SI was associated with increased risk of revised 3-point and 4-point MACE (HR=1.39 95% CI, 1.08–1.78 and 1.26 1.01–1.58, respectively). Among patients without prior HF (n=1,988), SI was associated with increased risk of HF hospitalization (HR=2.04 1.26–3.30). Patients with AMI and SI have an increased risk of MACE and incident HF hospitalization compared with patients with AMI without SI.
Nguyen et al. (Sun,) conducted a cohort in Acute myocardial infarction (n=3,149). Systemic inflammation (hsCRP 2-10 mg/L) vs. Without systemic inflammation (hsCRP <2 mg/L) was evaluated on Revised 3-point MACE (nonfatal MI, nonfatal stroke, or all-cause mortality) (HR 1.39, 95% CI 1.08-1.78). Systemic inflammation in acute myocardial infarction patients was associated with an increased risk of 3-point MACE compared to those without inflammation (HR 1.39; 95% CI 1.08-1.78).